Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience
Authors
Keywords
-
Journal
JOURNAL OF IMMUNOTHERAPY
Volume 45, Issue 5, Pages 254-262
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-04-11
DOI
10.1097/cji.0000000000000416
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
- (2021) Kathryn M. Cappell et al. Nature Reviews Clinical Oncology
- Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
- (2020) N. Nora Bennani et al. BLOOD
- Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
- (2020) Paul D. Brown et al. JOURNAL OF CLINICAL ONCOLOGY
- Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis
- (2020) Ahmed Abbasi et al. Journal of Hematology & Oncology
- CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain
- (2020) Tongjuan Li et al. Frontiers in Oncology
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- (2020) Marcela V Maus et al. Journal for ImmunoTherapy of Cancer
- Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy
- (2020) Khushali S. Jhaveri et al. Blood Advances
- Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma
- (2019) Matthew J. Frigault et al. BLOOD
- Managing the toxicities of CAR T‐cell therapy
- (2019) Sattva S. Neelapu HEMATOLOGICAL ONCOLOGY
- Successful anti‐CD19 CAR T‐cell therapy in HIV‐infected patients with refractory high‐grade B‐cell lymphoma
- (2019) Jeremy S. Abramson et al. CANCER
- CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma
- (2019) Tanya Siddiqi et al. BLOOD
- Diagnosis and Management of Dementia: Review
- (2019) Zoe Arvanitakis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma
- (2018) Tarec Christoffer El-Galaly et al. EUROPEAN JOURNAL OF CANCER
- Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
- (2018) Bianca D. Santomasso et al. Cancer Discovery
- Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema
- (2018) Matthew Torre et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
- (2018) Juliane Gust et al. CNS DRUGS
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary CNS Lymphoma
- (2017) Christian Grommes et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma
- (2017) Jeremy S. Abramson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
- (2016) Elise A. Chong et al. BLOOD
- Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients
- (2015) Meredith S. Shiels et al. CANCER
- Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial
- (2013) P. D. Brown et al. NEURO-ONCOLOGY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- How I treat HIV-associated lymphoma
- (2012) K. Dunleavy et al. BLOOD
- Use of memantine for the treatment of dementia
- (2011) Daphne Lo et al. Expert Review of Neurotherapeutics
- Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis
- (2010) Monika Müller et al. LANCET INFECTIOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started